Relmada Therapeutics Stock Investor Sentiment

RLMD Stock  USD 0.47  0.01  2.08%   
About 57% of all Relmada Therapeutics' shareholders are looking to take a long position. The analysis of overall sentiment of trading Relmada Therapeutics stock suggests that some investors are interested at this time. The current market sentiment, together with Relmada Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Relmada Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Relmada Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Relmada Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
2 days ago at gurufocus.com         
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Gurufocus Stories at Macroaxis
2 days ago at seekingalpha.com         
Relmada seeking strategic options, stock climbs 5
seekingalpha News
few days ago at thelincolnianonline.com         
Mizuho Reiterates Neutral Rating for Relmada Therapeutics
news
few days ago at thelincolnianonline.com         
Relmada Therapeutics Rating Lowered to Hold at Mizuho
news
few days ago at seekingalpha.com         
Relmada cut to neutral by Mizuho on Phase 3 study failure
seekingalpha News
six days ago at globenewswire.com         
Relmada Therapeutics Reports That Data Monitoring Committee Assessment Indicates That the Phase 3 Re...
Macroaxis News: globenewswire.com
six days ago at benzinga.com         
Relmada Therapeutics Stock Plummets Losing 80 percent Value - Heres Why
benzinga news
over two weeks ago at news.google.com         
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - Gur...
Google News at Macroaxis
over two weeks ago at gurufocus.com         
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm
Gurufocus Stories at Macroaxis
over two weeks ago at www.macroaxis.com         
Acquisition by Ence Chuck of 14500 shares of Relmada Therapeutics at 3.8657 subject to Rule 16b-3
Macroaxis News
over two weeks ago at gurufocus.com         
Relmada Therapeutics to Present at Jefferies London Healthcare Conference
Gurufocus Stories at Macroaxis
over three weeks ago at insidermonkey.com         
Relmada Therapeutics, Inc. Q3 2024 Earnings Call Transcript
insidermonkey News
over a month ago at gurufocus.com         
Relmada Therapeutics Inc Q3 2024 Earnings Call Highlights Navigating Financial ...
Gurufocus Stories at Macroaxis
over a month ago at finance.yahoo.com         
Relmada Therapeutics Inc Q3 2024 Earnings Call Highlights Navigating Financial ...
Yahoo News
over a month ago at globenewswire.com         
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Macroaxis News: globenewswire.com
Far too much social signal, news, headlines, and media speculation about Relmada Therapeutics that are available to investors today. That information is available publicly through Relmada media outlets and privately through word of mouth or via Relmada internal channels. However, regardless of the origin, that massive amount of Relmada data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Relmada Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Relmada Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Relmada Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Relmada Therapeutics alpha.

Relmada Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Relmada Therapeutics Stock Price Down 0.3 percent Heres What Happened
10/10/2024
2
Disposition of tradable shares by Ogorman Cedric of Relmada Therapeutics subject to Rule 16b-3
10/16/2024
3
Disposition of 13000 shares by Casamento Charles J of Relmada Therapeutics subject to Rule 16b-3
10/22/2024
4
Acquisition by Schmidt Eric Thomas of 57042 shares of Relmada Therapeutics subject to Rule 16b-3
10/28/2024
5
Relmada Therapeutics GAAP EPS of -0.72 misses by 0.08
11/07/2024
6
Relmada Therapeutics Inc Q3 2024 Earnings Call Highlights Navigating Financial ...
11/08/2024
7
Acquisition by Ence Chuck of 14500 shares of Relmada Therapeutics at 3.8657 subject to Rule 16b-3
11/20/2024
8
Relmada Therapeutics Stock Plummets Losing 80 percent Value - Heres Why
12/04/2024
9
Relmada Therapeutics Rating Lowered to Hold at Mizuho
12/06/2024
10
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
12/09/2024

Complementary Tools for Relmada Stock analysis

When running Relmada Therapeutics' price analysis, check to measure Relmada Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relmada Therapeutics is operating at the current time. Most of Relmada Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relmada Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relmada Therapeutics' price. Additionally, you may evaluate how the addition of Relmada Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing